Last updated: 02/16/2024 10:00:33

Subject insights to understand Rheumatoid Arthritis (RA)

GSK study ID
206577
See study documents
Clinicaltrials.gov ID
NCT03285191
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Rheumatoid Arthritis
Trial description: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting the joints and can lead to joint pain, swelling, redness and stiffness and can cause deformity, loss of strength and immobility. This cross-sectional qualitative study aims to explore the burden of established RA by conducting semi-structured Concept elicitation (CE) interviews (60 minutes duration) and real-time data capture task. The conceptual model developed from this data will be used to support the development of GSK3196165, a recombinant human monoclonal antibody (mAb) targeted for the treatment of RA. The CE interviews will explore the subject experience of RA and will collect information about symptoms, disease impact on functioning and health related quality of life (HRQoL), and treatment experiences/impacts of the condition and the language used by subjects to describe them. Following the CE interview, subjects will be asked to complete a brief symptom ranking exercise where they will need to rank how bothersome each RA symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS). After the interviews, the real-time disease experience of subjects will be captured by the real-time data capture app-based activity over a period of 7 days. Approximately 30 English-speaking subjects from the United States (US) with RA who are inadequate responders of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and/or (bDMARDs) will participate in the interviews and of these, 10 subjects will be offered the opportunity to participate in the real-time data capture sub study.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Number of subjects with RA participating in CE interviews

Timeframe: 1 day

Secondary outcomes:

Analysis of RA experience by using real-time data data capture task

Timeframe: Up to 7 days

Preparation of the conceptual model

Timeframe: Up to 7 days

Interventions:
  • Other: Numerical rating scale
  • Other: Real-time data capture app
    • Enrollment:
    30
    Primary completion date:
    2017-17-08
    Observational study model:
    Cohort
    Time perspective:
    Cross-Sectional
    Clinical publications:
    Not applicable
    Medical condition
    Arthritis, Rheumatoid
    Product
    Otilimab
    Collaborators
    Not applicable
    Study date(s)
    July 2017 to August 2017
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    No
    • Male or female, aged >=18 years or over.
    • Subject has a diagnosis of rheumatoid arthritis and has had this diagnosis for at least 6 months.
    • Subject has a history of other inflammatory rheumatological or autoimmune disorders that are not secondary to RA.
    • Subject has significant unstable or uncontrolled acute or chronic disease other than RA.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Male or female, aged >=18 years or over.
    • Subject has a diagnosis of rheumatoid arthritis and has had this diagnosis for at least 6 months.
    • Subject has a minimum of four swollen and tender joints.
    • Subject is either an inadequate responder to csDMARDs and has never received a bDMARD or an inadequate responder to bDMARDs (subject may be receiving bDMARDs only or may be continuing csDMARD treatment in addition to receiving a bDMARD).
    • Subject is willing and able to participate in the study and provide written informed consent.
    • Subject is a fluent US-English speaker and is able to read, write and fully understand the US-English language.
    • Subject is willing and able to participate in a 60-minute interview and optional app task to discuss their experience of rheumatoid arthritis. For subjects taking part in real-time data capture:
    • Subject owns/or has access to either a smartphone [iPhone Operating System (iOS) or android] or tablet which has video, audio/microphone and photographic capabilities and access to either the Apple app store or Google play store to download the app.
    • Subject is willing and able to take part in the real time data application task and respond to a series of questions/tasks fielded via the application over the course of seven days and is willing to respond to some brief questions following the real-time data capture task about their experience of using the app and completing the tasks, in a 5-10 minute telephone call.
    • Subject would feel comfortable recording short videos of themselves and providing audio commentary in response to app questions/tasks.
    Exclusion criteria:
    • Subject has a history of other inflammatory rheumatological or autoimmune disorders that are not secondary to RA.
    • Subject has significant unstable or uncontrolled acute or chronic disease other than RA.
    • Subject is unwilling or unable to comply with the requirements of the study or has a physical or mental condition that, in the opinion of the physician, may affect the subject's ability to participate in the study, the responses he/she might provide or their ability to provide consent.
    • Subject is currently or has previously been enrolled in a clinical trial for RA in the past year.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Bollington, Cheshire, United Kingdom, SK10 5JB
    Status
    Study Complete
    Contact us

    Study documents

    Study report synopsis
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)
    Statistical analysis plan
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2017-17-08
    Actual study completion date
    2017-17-08

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Results for study 206577 can be found on the GSK Clinical Study Register.
    Click here
    Access to clinical trial data by researchers
    Visit website